Pasithea

Contributing Author

Recent Articles by Pasithea

Jan-13	Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines KTTA GlobeNewswire
Dec-02	Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock KTTA GlobeNewswire
Nov-28	Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock KTTA GlobeNewswire
Nov-25	Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS KTTA GlobeNewswire
Nov-24	Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data KTTA GlobeNewswire
Nov-21	Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients KTTA GlobeNewswire
Nov-20	Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study KTTA GlobeNewswire
Nov-04	Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients KTTA GlobeNewswire
Sep-16	Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients KTTA GlobeNewswire
Sep-08	Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients KTTA GlobeNewswire
Aug-29	Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference KTTA GlobeNewswire
Aug-28	Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference KTTA GlobeNewswire
Jul-31	Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients KTTA GlobeNewswire
Jun-11	Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board KTTA GlobeNewswire
Jun-02	Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025 KTTA GlobeNewswire
May-20	Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases KTTA GlobeNewswire
May-14	Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site KTTA GlobeNewswire
May-07	Pasithea Therapeutics Announces Closing of $5 Million Public Offering KTTA GlobeNewswire
May-06	Pasithea Therapeutics Announces Pricing of $5 Million Public Offering KTTA GlobeNewswire
May-06	Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004 KTTA GlobeNewswire

Pasithea

Recent Articles by Pasithea

Upgrade your FINVIZ experience